Executive summary: US Patent 7,560,444 claims a pulmonary-delivery formulation in which a therapeutic/diagnostic polypeptide is linked to a depolymerized, low–molecular weight LMWH (avg. <8,000 Da) with reduced anticoagulant activity, optionally further defined by specific oligosaccharide “chemical signatures,” particle-size/physical-form parameters, and coupling chemistries (EDC or CNBH4/DMSO/AcOH). The claim set is broad on (i) pulmonary dosing vehicles and (ii) polypeptide identity (explicitly enumerated), but it is narrowed by the LMWH production constraint (depolymerization, avg. <8,000 Da), the required linkage between LMWH and polypeptide, and multiple structural/functional reductions of anti-Xa/anti-IIa activity tied to particular heparin fragment motifs. The most litigation-relevant risks for competitors are (a) whether their LMWH conjugate uses the same fragment/“signature” families that drive reduced anticoagulant activity and (b) whether they implement the same coupling/linking concept to produce a conjugate rather than a co-formulation.

US Patent 7,560,444 (pulmonary delivery polypeptide linked LMWH) claims and patent landscape analysis

US 7,560,444’s independent claim 1 is a formulation claim; independent claim 22 is a method-of-preparation claim. Dependent claims add specificity on LMWH fragment length (hexasaccharide or octasaccharide+), polypeptide examples, polypeptide molecular weight windows, delivery device/form-factor (pressurized container), physical formulation (dry/particle-size or liquid/aerosol), coupling reagents (EDC or CNBH4/DMSO/AcOH), and reduced anticoagulant activity thresholds (≥50% anti-Xa/anti-IIa reduction vs. commercial heparins), including reduction achieved by modifying particular heparin “chemical signatures.”

What is the core invention in US 7,560,444?

Featured snippet answer: A pulmonary delivery formulation where a polypeptide is chemically linked to a depolymerized LMWH fragment (avg. <8,000 Da) with reduced anti-Xa/anti-IIa activity, optionally characterized by specific heparin oligosaccharide motifs and provided in a pulmonary delivery device.

Claim-1 claim architecture (key elements competitors must map)

Claim 1 requires all of:

Pulmonary delivery formulation of a therapeutic or diagnostic polypeptide.
A polypeptide + LMWH produced by a depolymerization method.
LMWH average molecular weight < 8,000 Da.
The LMWH is linked to the polypeptide (not merely mixed/co-administered).
Reduced anticoagulant activity is not explicitly in claim 1 text as provided, but later claims (23, 35-36, 43) do specify reduction vs reference heparins; claim scope can still be interpreted through the full set.
The formulation is provided in a device for pulmonary delivery.

Claim-22 claim architecture (manufacturing infringement hook)

Claim 22 requires:

Combining the polypeptide with depolymerized LMWH (<8,000 Da avg.).
Linking LMWH and polypeptide to prepare a pulmonary formulation.
Amounts sufficient for pulmonary delivery.
Later dependents add device delivery and enhancer additives.

What patents cover the same pulmonary LMWH-polypeptide conjugate concept as US 7,560,444?

Featured snippet answer: The landscape will cluster around (i) pulmonary delivery of proteins/peptides via inhalation devices, (ii) heparin/LMWH fragment chemistry and reduced anticoagulant activity via controlled depolymerization and oligosaccharide motif modification, and (iii) polymer/polysaccharide-protein conjugation chemistry using coupling reagents and defined fragment lengths.

How the claim language narrows “covered subject matter”

The following constraints are the most leverage points for assessing whether other patents/efforts overlap:

Depolymerized LMWH: “LMWH produced by a method that includes depolymerization” (sets a manufacturing/starting-material constraint).
Molecular weight cutoff: avg. molecular weight < 8,000 Da.
Conjugation requirement: LMWH must be linked to polypeptide.
Optional but litigation-critical structural motifs: specific ΔU H-NAc/6SG H motifs and signature fragments.
Anticoagulant reduction: at least one dependent claim ties anti-Xa/anti-IIa reduction to modified signatures.
Pulmonary delivery device: pressurized container/dispenser in dependents; aerosol/mist/suspension or dry formulation in dependents.

Patent estate mapping approach (what matters in practice)

When building an infringement or freedom-to-operate map around US 7,560,444, the relevant adjacent patent buckets usually include:

Pulmonary delivery of polypeptides using specific formulations (dry powder particle sizing, aerosols, mist).
Heparin/LMWH depolymerization to oligosaccharides and reduced anticoagulant fragments.
Non-anticoagulant or low-anticoagulant heparin derivatives defined by anti-Xa/anti-IIa activity reduction.
Protein conjugation with polysaccharides with defined coupling chemistries (EDC or reductive amination systems like CNBH4/DMSO/AcOH).
Device/form-factor claims for pulmonary delivery (pressurized dispensers).

Operational takeaway: If competitor products use (a) non-conjugated coformulation, (b) LMWH with avg. ≥ 8,000 Da, (c) a different anticoagulant reduction mechanism not tied to these motifs, or (d) a different coupling chemistry and structure that does not satisfy “linked” requirements, the claim coverage can collapse quickly.

How broad are the claim terms for US 7,560,444, and where are the real limiting factors?

Featured snippet answer: The patent is broad across polypeptide identity and delivery modality but is limited by the conjugate nature (LMWH linked to the polypeptide), depolymerized low-MW LMWH (<8,000 Da), and optional but highly specific reductions in anti-Xa/anti-IIa activity tied to specific oligosaccharide signature structures.

Polypeptide coverage: enumerated but very wide

Claim 5 enumerates many proteins and biologics; claim 6 expands the list dramatically (including insulin variants, EPO variants, interferons, monoclonal antibodies, cytokines, growth factors, enzymes, and others). Practically, this means a competitor cannot “design around” by choosing a different polypeptide if it falls within the enumerated set or within reasonable interpretation of “therapeutic or diagnostic polypeptide” if that phrase is construed broadly beyond the enumerations in dependents.

Litigation sensitivity

Dependent claims that add enumeration can still create infringement pressure if the accused product matches a listed protein.
The independent claim 1 covers “therapeutic or diagnostic polypeptide,” which can be read broadly.

LMWH constraints: the main narrowing

Claim 1’s LMWH constraint plus the depolymerization requirement create a clear technical boundary:

Depolymerization method is required (not just any LMWH).
Average molecular weight < 8000 Da is required.
Certain dependents add hexasaccharide and octasaccharide or larger polysaccharide length constraints.
Several dependents tie to anti-Xa/anti-IIa reduction by ≥50% and signature motif modifications.

Device and formulation mode: additional narrowing in dependents

Pressurized container/dispenser (claim 11).
Dry formulation with particle-size means geometric diameter 1–500 μm; nested range 2–100 μm (claims 18–20).
Liquid/aerosol/mist/suspension (claim 21). If an accused product uses a fundamentally different pulmonary system (e.g., nebulizer category outside the claim interpretations), it can help in design-around and claim construction.

When does US 7,560,444 lose exclusivity for pulmonary formulations?

No answer can be produced from the information provided. Patent expiration depends on priority filing date, prosecution history, patent term adjustments, and any terminal disclaimers. The claim text alone does not supply the filing/priority timeline required to compute expiration or exclusivity.

What are the most important dependent claims for infringement risk (1 vs 2-43)?

Featured snippet answer: The highest infringement leverage comes from dependent claims that (i) define specific LMWH fragment sizes (hexasaccharide/octa+), (ii) require reduced anti-Xa/anti-IIa activity by ≥50% vs reference commercial LMWHs, (iii) require signature-structure modifications, and (iv) require specific linkage/coupling chemistries (EDC or CNBH4/DMSO/AcOH). Competitors that avoid conjugation, avoid avg. <8,000 Da depolymerized fragments, or avoid the signature/functional reduction nexus are best positioned.

Claim-specific risk matrix (conceptual)

Claim	Adds to independent claim 1/22	Likely infringement hinge
2-4	LMWH list; hexasaccharide or octasaccharide+	Whether accused LMWH falls in specific fragment-size and species list
5-6, 27-28	Specific polypeptide identities	Whether product protein matches enumerated set
7-9, 29-31	Polypeptide MW windows	Whether protein falls in defined MW ranges
10, 32	Delivery enhancer inclusion	Whether formulation includes enhancer (depends on product)
11, 34	Pressurized container/dispenser	Device form-factor and classification
12	Modified LMWH charge/size/activity	Whether LMWH modifications are achieved by charge/size changes
13-16	Two to twenty disaccharides; specific signature motifs	Structural characterization of fragment motifs
17, 38	Coupling reagents (EDC; CNBH4/DMSO/AcOH)	Coupling chemistry and resulting linkage type
18-20	Dry formulation and particle size distribution	Dry powder mean geometric diameter
21	Liquid/aerosol/mist/suspension	Liquid pulmonary mode
23-26	Anti-Xa/anti-IIa reduced ≥50% vs reference + size/charge reduction	Functional anticoagulant reduction requirement and reference standard comparison
35-36	Signature modifications used to reduce anti-Xa	Signature-based mechanism for reduction
37	Monosaccharide/disaccharide added/removed; acetyl/sulfo modifications	Detailed structural tweak set for signature motifs
39-40	Hexasaccharide or octa+ in method claim	Fragment length control
41-43	Example formulation(s) anchored to hGH and including reduced anti-Xa via signatures	Product-specific infringement if hGH formulation is at issue

How strong are the “signature motif” claims for US 7,560,444?

Featured snippet answer: The signature-motif dependents (claims 16, 35-36, 43, and related) strengthen validity against generic “LMWH fragments” by tying reduced anticoagulant activity to specific heparin oligosaccharide structures. The enforceability will turn on whether accused LMWH fragments can be characterized to match those ΔU H-NAc/6SG H motifs and whether the same motif modifications are used to obtain ≥50% anti-Xa/anti-IIa reduction.

Practical enforceability considerations (claim construction issues that matter)

Structural identification: “chemical signature… determined” requires technical proof that the fragment motif exists and that it was modified per claim language.
Causation vs correlation: claims 35-36/43 require reduction “by modification” of the signature, not merely incidental reduction.
Combinatorial breadth: motifs listed are finite, but each motif can encompass isomer/variant degrees of freedom unless the patent’s definitions lock down exact saccharide sequence and modification positions. The provided claim text lists motifs but does not give full structural encoding beyond shorthand sequences.

How does US 7,560,444 treat anticoagulant activity reduction, and what design-arounds are plausible from the claim wording?

Featured snippet answer: Claim 23 requires ≥50% reduction in anti-Xa and/or anti-IIa vs reference commercial heparins; claim 35-36/43 ties the reduction to specific chemical signature modifications of heparin oligosaccharides. Design-arounds focus on avoiding those modifications and/or ensuring the anticoagulant reduction thresholds are not met in the same functional way.

Key functional constraints

Claim 23: “anti-Xa activity and/or anti-IIa activity is reduced by at least 50% … compared to” reference standard (unfractionated heparin and specific LMWHs like enoxaparin, dalteparin, reviparin, tinzaparin, nadroparin, certoparin, ardeparin, parnaparin).
Claim 43: similar reduction requirement plus signature-based modification requirement.

Design-around levers suggested by claim language

Use depolymerized <8,000 Da LMWH that is conjugated but does not achieve ≥50% anti-Xa/anti-IIa reduction versus those reference standards.
Achieve low anticoagulant activity through different chemical modifications not captured by the listed signature motif modifications.
Avoid matching the explicit coupling chemistry if coupling is a claim element (EDC or CNBH4/DMSO/AcOH appears in dependents; products can still fall under independent “linked” if “linked” is met).
Avoid fragment length constraints (hexasaccharide or octa+ dependents) if the accused material uses different saccharide length distributions.

What does US 7,560,444 claim about pulmonary delivery devices and physical formulation?

Featured snippet answer: It covers pulmonary delivery formulations of LMWH-polypeptide conjugates in both liquid/aerosol/mist forms and dry powder/dry formulations, including pressurized containers/dispensers and specific dry-particle size distributions (mean geometric diameter).

Dry formulation: particle size is a concrete claim limiter

Claim 18: dry formulation.
Claim 19: LMWH particles mean geometric diameter 1–500 microns.
Claim 20: nested range 2–100 microns.

This is a strong infringement filter if an accused product uses markedly different particle sizing or formulation classes.

Pressurized dispenser

Claim 11: pressurized container or dispenser.
Claim 34: same limitation in method claim.

If an accused device is a different pulmonary delivery category (different dispensing mechanism and device claim construction), those dependents may not be implicated.

How does US 7,560,444 overlap with biosimilar or monoclonal antibody formulations?

Featured snippet answer: The claim list includes multiple biologics and monoclonal antibodies in dependent claims (claim 6), but the core system is a pulmonary delivery formulation with a conjugated depolymerized LMWH fragment. That means risk attaches to the conjugate system, not the biological target alone.

Target-type vs platform-type infringement

A competitor could select a different biologic/antibody and still infringe if it uses the same LMWH conjugate platform and device/form requirements.
Conversely, using the same polypeptide as listed does not guarantee infringement unless the LMWH conjugate, depolymerization and molecular weight constraints, and linkage requirement are met.

What patent litigation and Orange Book status affect US 7,560,444?

No answer can be produced from the information provided. Determining Orange Book status requires the relevant FDA application(s) and listed patents tied to specific NDA/BLA entries; litigation status requires case identifiers and dockets. The claim text does not supply this.

Key takeaways

US 7,560,444 is a platform-style patent: it claims pulmonary delivery of polypeptides using a linked conjugate with depolymerized LMWH fragments averaging <8,000 Da.
The broadest infringement exposure is from the independent formulation/method claims that do not require a specific polypeptide identity and only require “linked” LMWH-polypeptide conjugation in a pulmonary delivery device context.
The strongest technical narrowing, and likely the center of validity and infringement disputes, lies in dependents that require:
- specific LMWH fragment sizing (hexasaccharide, octasaccharide or larger),
- functional anticoagulant reduction (≥50% anti-Xa/anti-IIa vs reference heparins),
- and signature-structure motif modifications tied to the ΔU H-NAc/6SG H-like oligosaccharide shorthand.
Competitors can reduce risk by targeting one or more hard claim constraints: avoiding conjugation (as opposed to coformulation), using LMWH outside avg. <8,000 Da depolymerized fragment bounds, or avoiding the specific signature motif modifications that produce the claimed anticoagulant reduction.

FAQs

Do the “linked” requirement and coupling chemistry dependents control infringement even if my product uses a different coupling reagent than EDC or CNBH4/DMSO/AcOH?
If my LMWH fragment averages slightly above 8,000 Da, can I still fall into the claim scope via a narrower subpopulation that is <8,000 Da?
How do courts typically treat shorthand “chemical signature” motif language when evaluating infringement against an accused heparin fragment that is characterized by different analytical descriptors?
For dry powder pulmonary products, how decisive are mean geometric particle diameter limits (1–500 μm; 2–100 μm) when the distribution tail extends outside the claimed range?
Does using a polypeptide not listed in dependent claims avoid infringement under claim 1’s “therapeutic or diagnostic polypeptide” language if the conjugate system is the same?

References

US Patent 7,560,444.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	June 23, 1987	⤷ Start Trial	2024-10-01
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	October 16, 1986	⤷ Start Trial	2024-10-01
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	February 04, 1999	⤷ Start Trial	2024-10-01
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	October 08, 1996	⤷ Start Trial	2024-10-01
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 7,560,444

Summary for Patent: 7,560,444